Literature DB >> 18987181

Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels.

David R Riddell1, Hua Zhou, Kevin Atchison, Helen K Warwick, Peter J Atkinson, Julius Jefferson, Lin Xu, Suzan Aschmies, Yolanda Kirksey, Yun Hu, Erik Wagner, Adrienne Parratt, Jane Xu, Zhuting Li, Margaret M Zaleska, J Steve Jacobsen, Menelas N Pangalos, Peter H Reinhart.   

Abstract

Inheritance of the apoE4 allele (epsilon4) increases the risk of developing Alzheimer's disease; however, the mechanisms underlying this association remain elusive. Recent data suggest that inheritance of epsilon4 may lead to reduced apoE protein levels in the CNS. We therefore examined apoE protein levels in the brains, CSF and plasma of epsilon2/2, epsilon3/3, and epsilon4/4 targeted replacement mice. These apoE mice showed a genotype-dependent decrease in apoE levels; epsilon2/2 >epsilon3/3 >epsilon4/4. Next, we sought to examine the relative contributions of apoE4 and apoE3 in the epsilon3/4 mouse brains. ApoE4 represented 30-40% of the total apoE. Moreover, the absolute amount of apoE3 per allele was similar between epsilon3/3 and epsilon3/4 mice, implying that the reduced levels of total apoE in epsilon3/4 mice can be explained by the reduction in apoE4 levels. In culture medium from epsilon3/4 human astrocytoma or epsilon3/3, epsilon4/4 and epsilon3/4 primary astrocytes, apoE4 levels were consistently lower than apoE3. Secreted cholesterol levels were also lower from epsilon4/4 astrocytes. Pulse-chase experiments showed an enhanced degradation and reduced half-life of newly synthesized apoE4 compared with apoE3. Together, these data suggest that astrocytes preferentially degrade apoE4, leading to reduced apoE4 secretion and ultimately to reduced brain apoE levels. Moreover, the genotype-dependent decrease in CNS apoE levels, mirror the relative risk of developing AD, and suggest that low levels of total apoE exhibited by epsilon4 carriers may directly contribute to the disease progression, perhaps by reducing the capacity of apoE to promote synaptic repair and/or Abeta clearance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987181      PMCID: PMC6671315          DOI: 10.1523/JNEUROSCI.1972-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  67 in total

1.  Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse.

Authors:  H Sheng; D T Laskowitz; G B Mackensen; M Kudo; R D Pearlstein; D S Warner
Journal:  Stroke       Date:  1999-05       Impact factor: 7.914

2.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.

Authors:  Y Huang; X Q Liu; T Wyss-Coray; W J Brecht; D A Sanan; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.

Authors:  H C O'Donnell; J Rosand; K A Knudsen; K L Furie; A Z Segal; R I Chiu; D Ikeda; S M Greenberg
Journal:  N Engl J Med       Date:  2000-01-27       Impact factor: 91.245

4.  Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis.

Authors:  T Siddique; M A Pericak-Vance; J Caliendo; S T Hong; W Y Hung; J Kaplan; D McKenna-Yasek; J B Rimmler; P Sapp; A M Saunders; W K Scott; N Siddique; J L Haines; R H Brown
Journal:  Neurogenetics       Date:  1998-03       Impact factor: 2.660

5.  Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E.

Authors:  R L Raffai; L M Dong; R V Farese; K H Weisgraber
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.

Authors:  F Fazekas; S Strasser-Fuchs; H Kollegger; T Berger; W Kristoferitsch; H Schmidt; C Enzinger; M Schiefermeier; C Schwarz; B Kornek; M Reindl; K Huber; R Grass; G Wimmer; K Vass; K H Pfeiffer; H P Hartung; R Schmidt
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

7.  Apo E structure determines VLDL clearance and atherosclerosis risk in mice.

Authors:  C Knouff; M E Hinsdale; H Mezdour; M K Altenburg; M Watanabe; S H Quarfordt; P M Sullivan; N Maeda
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

8.  Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion.

Authors:  F White; J A Nicoll; A D Roses; K Horsburgh
Journal:  Neurobiol Dis       Date:  2001-08       Impact factor: 5.996

9.  Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities.

Authors:  T Sabo; L Lomnitski; A Nyska; S Beni; R R Maronpot; E Shohami; A D Roses; D M Michaelson
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

10.  Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent.

Authors:  U Beffert; J S Cohn; C Petit-Turcotte; M Tremblay; N Aumont; C Ramassamy; J Davignon; J Poirier
Journal:  Brain Res       Date:  1999-10-02       Impact factor: 3.252

View more
  151 in total

1.  Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Authors:  John M Ringman; David Elashoff; Daniel H Geschwind; Brian T Welsh; Karen H Gylys; Cathy Lee; Jeffrey L Cummings; Greg M Cole
Journal:  Arch Neurol       Date:  2012-06

2.  Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study.

Authors:  Po H Lu; Paul M Thompson; Alex Leow; Grace J Lee; Agatha Lee; Igor Yanovsky; Neelroop Parikshak; Theresa Khoo; Stephanie Wu; Daniel Geschwind; George Bartzokis
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum.

Authors:  Haim Belinson; Daniel M Michaelson
Journal:  J Neural Transm (Vienna)       Date:  2009-04-16       Impact factor: 3.575

4.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

Review 5.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

6.  Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Craig Stockmeier; Xiaoming Ou; Ian Paul; Thomas Mosley; Karl Weisgraber; Jun Ming Wang
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

Review 7.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

8.  ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo.

Authors:  Sonya B Dumanis; Joseph A Tesoriero; Lenard W Babus; Madeline T Nguyen; Justin H Trotter; Mary Jo Ladu; Edwin J Weeber; R Scott Turner; Baoji Xu; G William Rebeck; Hyang-Sook Hoe
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

9.  APOE genotype-dependent modulation of astrocyte chemokine CCL3 production.

Authors:  Eiron Cudaback; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Glia       Date:  2014-08-04       Impact factor: 7.452

10.  APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Authors:  Katherine L Youmans; Leon M Tai; Evelyn Nwabuisi-Heath; Lisa Jungbauer; Takahisa Kanekiyo; Ming Gan; Jungsu Kim; William A Eimer; Steve Estus; G William Rebeck; Edwin J Weeber; Guojun Bu; Chunjiang Yu; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.